Marion Mccourt Sells 1,100 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) EVP Marion Mccourt sold 1,100 shares of the stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $656.97, for a total transaction of $722,667.00. Following the completion of the transaction, the executive vice president now directly owns 19,644 shares of the company’s stock, valued at $12,905,518.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Marion Mccourt also recently made the following trade(s):

• On Friday, April 1st, Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $701.82, for a total transaction of $701,820.00.

Shares of REGN stock opened at $660.49 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $478.40 and a 12 month high of $747.42. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.56 and a quick ratio of 3.07. The firm has a market capitalization of $71.69 billion, a P/E ratio of 9.16, a P/E/G ratio of 1.18 and a beta of 0.25. The company’s fifty day moving average price is $676.32 and its two-hundred day moving average price is $642.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last released its earnings results on Friday, February 4th. The biopharmaceutical company reported $23.72 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $18.49 by $5.23. The company had revenue of $4.95 billion during the quarter, compared to the consensus estimate of $4.49 billion. Regeneron Pharmaceuticals had a net margin of 50.24% and a return on equity of 55.11%. The company’s revenue was up 104.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $8.72 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 42.82 EPS for the current year.

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. grew its position in shares of Regeneron Pharmaceuticals by 2.6% during the 4th quarter. BlackRock Inc. now owns 9,610,871 shares of the biopharmaceutical company’s stock valued at $6,069,457,000 after buying an additional 244,009 shares during the last quarter. State Street Corp grew its position in shares of Regeneron Pharmaceuticals by 3.4% during the 4th quarter. State Street Corp now owns 4,799,822 shares of the biopharmaceutical company’s stock valued at $3,031,184,000 after buying an additional 159,817 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Regeneron Pharmaceuticals by 11.9% during the 4th quarter. JPMorgan Chase & Co. now owns 4,591,529 shares of the biopharmaceutical company’s stock valued at $2,899,642,000 after buying an additional 489,084 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Regeneron Pharmaceuticals by 13.6% during the 4th quarter. Geode Capital Management LLC now owns 1,977,302 shares of the biopharmaceutical company’s stock valued at $1,245,725,000 after buying an additional 237,090 shares during the last quarter. Finally, Putnam Investments LLC grew its position in shares of Regeneron Pharmaceuticals by 43.1% during the 3rd quarter. Putnam Investments LLC now owns 1,342,754 shares of the biopharmaceutical company’s stock valued at $812,608,000 after buying an additional 404,567 shares during the last quarter. 83.83% of the stock is owned by institutional investors and hedge funds.

REGN has been the subject of a number of research analyst reports. Piper Sandler increased their target price on shares of Regeneron Pharmaceuticals from $690.00 to $692.00 and gave the company an “overweight” rating in a report on Friday, February 4th. Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $640.00 to $645.00 in a research note on Wednesday, April 20th. Barclays raised their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $754.00 to $728.00 and set a “buy” rating for the company in a research note on Tuesday, February 8th. Finally, Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $640.00 to $645.00 in a research note on Wednesday, April 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $724.63.

About Regeneron Pharmaceuticals (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Articles